EU Says Novavax Vaccines Delayed After Material Shortage
- And Maryland based company Novavax is delaying signing a contract to supply its COVID-19 vaccine to the European Union. The EU tells Reuters News that the US biotech company warned that it was struggling to source some raw materials. This has complicated the goal to ship at least 100 million doses to Europe. The news caused the company's stock to drop 15%.